Europe ends in the red
Markets in Europe ended the trading session on Monday with losses as investors focused on latest developments regarding Britain’s withdrawal from the European Union. United Kingdom Prime Minister Theresa May’s spokesman confirmed earlier that the meaningful vote on her Brexit divorce deal in Parliament would take place next week.
The FTSE 100 closed 0.39% lower, dragged down by the consumer goods shares. The CAC 40 declined 0.38% at the end of the session. Sanofi, Danone and Airbus were the biggest losers, dropping 1.99%, 1.84% and 1.83%, respectively. The German DAX fell 0.18% at the closing bell. Bayer declined 1.59%, followed by Siemens, which decreased 1.31%.
Huawei sues US Company in China
Huawei Technologies sued the United States-based company InterDigital in Shenzhen, China, alleging wrongdoing regarding intellectual property use terms.
According to the regulatory document, filed at the Shenzhen Intermediate People’s Court last Wednesday, the lawsuit alleges InterDigital for infringing an obligation to license patents crucial to 3G, 4G and 5G wireless telecommunication standards, on non-discriminatory terms and conditions.
Shares of the Delaware-based wireless tech solutions company were down 6.55% in the last thirty days, declining over 20% in the last six months
Bristol Mayer Squibb takeover on the Fitch radar
The deal reached by Bristol-Myers Squibb Co. to purchase Celgene Corp. for $74 billion prompted Fitch Ratings to place the pharmaceutical firm under negative watch. Fitch said, the transaction, which includes $32 billion in debt and another $20 billion in assumed liabilities, compares to the $7.2 billion outstanding that was registered as of the end of September and is graded A-.
The acquisition, projected to be executed in the third quarter, brings "additional breadth and depth in the oncology and immunology markets" in the late-stage project portfolio, the credit appraiser acknowledged and added six product launches are possible. It also highlighted the potential benefits from diversification.
Bristol-Myers Squibb depends on the implementation of the takeover plan’s nominal $2.5 billion in synergies. The new entity’s operating profile places it in a higher league, the agency said and named Pfizer and Merck, but it added "the breadth, depth, and patent risk of a combined Bristol-Celgene would compare less favourably." The short-term issuer default rating was held at F2.
Amazon becomes most valuable US Company
Amazon.com Inc. emerged as the biggest listed entity in the United States by market capitalization in intraday trading, following turbulence which has cost Apple its long-lasting first place. The online retail giant has attempted and failed to close at the top valuation last month. Today it overtook Microsoft for the best position, reaching $1,626.5 per share, the highest mark since December 14 and eyeing $800 billion. Amazon has briefly topped $1 trillion in September, the only company after Apple to achieve the milestone.
The Calamatta Cuschieri Traders Blog is available daily on CC WebTrader. Other market coverage including coverage of the International Bond Markets is also available.
The information provided on this website is being provided solely for educational and informational purposes and should not be construed as investment advice, advice concerning particular investments or investment decisions, or tax or legal advice. Similarly any views or opinions expressed on this website are not intended and should not be construed as being investment, tax or legal advice or recommendations. Investment advice should always be based on the particular circumstances of the person to whom it is directed, which circumstances have not been taken into consideration by the persons expressing the views or opinions appearing on this website. Calamatta Cuschieri & Co. Ltd. (CC) has not verified and consequently neither warrants the accuracy nor the veracity of any information, views or opinions appearing on this website. You should always take professional investment advice in connection with, or independently research and verify, any information that you find or views or opinions which you read on our website and wish to rely upon, whether for the purpose of making an investment decision or otherwise. CC does not accept liability for losses suffered by persons as a result of information, views or opinions appearing on this website.
This website is owned and operated by Calamatta Cuschieri & Co. Ltd (Co. Reg. No. C13729) of 5th Floor, Valletta Buildings, South Street, Valletta VLT 1103, Malta. CC is licensed to conduct Investment Services in Malta by the Malta Financial Services Authority.